TL;DR
The developed transethosomal system showed favorable physicochemical properties, sustained drug release, stability, antioxidant and antimicrobial activity, and significant cytotoxicity against melanoma cells, which support its potential as a multifunctional topical platform for localized melanoma therapy and provide a basis for future in vivo evaluation.
Improved Cabozantinib delivery via Cabozantinib-loaded poly(lactic-co-glycolic acid) nanoparticles, prepared by solvent evaporation represents improved Cabozantinib delivery via Cabozantinib-loaded poly(lactic-co-glycolic acid) nanoparticles that overcomes pharmacokinetic pitfalls of CBZT.
Findings support the LZ-loaded bilosomal gel as a controlled topical delivery system and support further evaluation of the LZ-loaded bilosomal gel.
The NLC formulations studied, particularly NX-ST, effectively enhanced HU's therapeutic performance by improving stability, delivery efficiency, and anticancer activity.
Overall, the developed transferosomal system demonstrated improved permeation, sustained release, and biocompatibility, suggesting its potential as a promising topical delivery.
Results demonstrate PLGA-DOX/RV as a potent localized therapy for periodontitis as well as demonstrating its ability to reduce alveolar bone loss in vitro and in vivo.
NLPs improved Iso's bioavailability and anticancer efficacy, supporting their potential for further studies in breast cancer therapy and supporting their potential for further studies in breast cancer therapy.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
